A Novel Insulin Combination of Insulin Degludec and Insulin Aspart Achieves a More Stable Overnight Glucose Profile than Insulin Glargine: Results from Continuous Glucose Monitoring in a Proof-of-Concept Trial

Documenti analoghi

• A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
  di: Heise, Tim, et al.
  Pubblicazione: (2011)
• Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
  di: Kumar, Ajay, et al.
  Pubblicazione: (2016)
• Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
  di: Hirsch, Irl B., et al.
  Pubblicazione: (2012)
• Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
  di: Sorli, Christopher, et al.
  Pubblicazione: (2013)
• Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
  di: Kalra, Sanjay
  Pubblicazione: (2016)